Thomas Leggett's Net Worth
$333 Thousand
Who is Thomas Leggett?
Thomas Leggett does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Research Alliance Corp. II, Axcella Health Inc., Black Diamond Therapeutics, Inc., and Stoke Therapeutics, Inc..
SEC CIK
Thomas Leggett's CIK is 0001774690
Past Insider Trading and Trends
2020 was Thomas Leggett's most active year for acquiring shares with 5 total transactions. Thomas Leggett's most active month to acquire stocks was the month of December. 2020 was Thomas Leggett's most active year for disposing of shares, totalling 9 transactions. Thomas Leggett's most active month to dispose stocks was the month of November. 2021 saw Thomas Leggett paying a total of $32,580.00 for 78,000 shares, this is the most they've acquired in one year. In 2021 Thomas Leggett cashed out on 6,000 shares for a total of $101,820.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Research Alliance Corp. II No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Axcella Health Inc. (AXLA) No price found
SVP Finance, CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Black Diamond Therapeutics, Inc. (BDTX) Snapshot price: $5.4
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4
|
—
|
0
|
$22.40 | -$69,240.00 |
0
|
Scheduled
|
Jan 8
| ||
Form 4
|
—
|
0
|
$22.32 | -$68,746.80 |
0
|
Scheduled
|
Dec 8
| ||
Form 4
|
—
|
0
|
$21.91 | -$66,311.70 |
0
|
Scheduled
|
Nov 9
| ||
Form 4
|
—
|
0
|
$22.20 | -$67,995.90 |
0
|
Scheduled
|
Oct 8
| ||
Form 4
|
—
|
0
|
$20.93 | -$60,420.00 |
0
|
Scheduled
|
Sep 14
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Stoke Therapeutics, Inc. (STOK) Snapshot price: $14.7
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||